ERBB2 and breast carcinoma: To identify injury-induced changes in the plasma membrane proteome we used MCF7 breast cancer cells expressing a N-terminally truncated 95 kDa version of ErbB2 (p95ErbB2), which increases their membrane dynamics and invasiveness28,29.